Organization
UCB Pharma, Monheim am Rhein, Germany
2 abstracts
Abstract
ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOLOrg: UCB Pharma, Slough, United Kingdom, UCB Pharma, Monheim am Rhein, Germany,
Abstract
BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIESOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom, Copenhagen University Hospital, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America, Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom,